AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

11.610

-0.250-2.11%

Volume:73.83K

Turnover:866.01K

Market Cap:582.83M

PE:16.17

High:11.930

Open:11.850

Low:11.550

Close:11.860

52wk High:13.933

52wk Low:9.365

Shares:50.20M

Float Shares:41.32M

Volume Ratio:0.42

T/O Rate:0.18%

Dividend:0.05

Dividend Rate:0.43%

EPS(TTM):0.718

EPS(LYR):0.718

ROE:16.30%

ROA:11.37%

PB:2.42

PE(LYR):16.17

Loading ...

Overview Company News Filings

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2

MT Newswires Live

ASX Growth Companies With High Insider Ownership January 2026

Simply Wall St.

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Simply Wall St.

Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate

MT Newswires Live

Clinuvel Pharmaceuticals Says Four Patients Reported Satisfaction in Vitilgo Treatment Study

MT Newswires Live

Artrya And 2 Other High Growth Tech Stocks With Potential In Australia

Simply Wall St.

Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq

MT Newswires Live

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development

Simply Wall St.

Is Clinuvel (ASX:CUV) Using Its Singapore Peptide Hub To Quietly Redefine Its Pipeline Ambitions?

Simply Wall St.

BRIEF-Clinuvel Pharmaceuticals Expands Singapore Rd&I Centre To Pioneer Next-Generation Peptide Therapies

BUZZ-Australia's Clinuvel jumps on expansion of Singapore R&D hub

Clinuvel Expands Research, Development Center in Singapore

MT Newswires Live

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator

MT Newswires Live

High Growth Tech Stocks in Australia for November 2025

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Insights After SEC Review Delay and Share Price Dip

Simply Wall St.

Clinuvel Pharmaceuticals Expects US Shutdown to Impact ADR Program Upgrade Deadlines

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-Update on Adr Upgrade, Nasdaq Uplisting

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":11.61,"timestamp":1771305120000,"preClose":11.86,"halted":0,"volume":73828,"delay":0,"changeRate":-0.021079258010118045,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.717999,"marketStatus":"Not Yet Opened","change":-0.25,"latestTime":"02-17 16:12:00 AEDT","open":11.85,"high":11.93,"low":11.55,"amount":866009,"amplitude":0.03204,"askPrice":11.9,"askSize":236,"bidPrice":11.41,"bidSize":466,"shortable":3,"etf":0,"ttmEps":0.717999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771369200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":11.86,"dividendRate":0.004307,"openAndCloseTimeList":[[1771282800000,1771304400000]],"volumeRatio":0.421464,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"11.37%","roe":"16.30%","lyrEps":0.717999,"volumeRatio":0.421464,"shares":50200740,"dividePrice":0.05,"high":11.93,"amplitude":0.03204,"preClose":11.86,"low":11.55,"week52Low":9.365,"pbRate":"2.42","psRate":"6.13","week52High":13.933,"institutionHeld":0,"latestPrice":11.61,"committee":0.327635,"eps":0.717999,"divideRate":0.004307,"volume":73828,"delay":0,"ttmEps":0.717999,"open":11.85,"prevYearClose":12.46,"prevWeekClose":10.6,"prevMonthClose":11,"prevQuarterClose":12.46,"fiveDayClose":11.62,"twentyDayClose":12.48,"sixtyDayClose":10.88,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"},{"date":"2024-08-29","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"","dateTimestamp":1724853600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608307388","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608307388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608307388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:06","pubTimestamp":1770145565,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dynamic environment, high-growth tech stocks can offer intriguing opportunities for investors seeking innovation and resilience amidst economic shifts and evolving global strategies.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","XAO.AU","CGS.AU","PYC.AU","BK7508","BK7067","XKO.AU","CUV.AU","XJO.AU"],"gpt_icon":0},{"id":"2608839722","title":"Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608839722","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608839722?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:47","pubTimestamp":1770004022,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  anticipates the receipt of Health Canada's marketing authorization decision for its drug candidate Scenesse for the treatment of vitiligo in the second half of 2026, according to a Monday Australian bourse filing.The company also expects to report top-line preclinical results from its controlled-release liquid injectable platform candidate, VLRX-L, study in the first half, the filing said.The company's shares shed about 1% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2607545890","title":"ASX Growth Companies With High Insider Ownership January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607545890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607545890?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:09","pubTimestamp":1769713763,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty with flat trading and cautious investor sentiment following the U.S. Federal Reserve's recent decision to hold interest rates steady, attention turns to how local indices will respond to upcoming announcements from the Reserve Bank of Australia. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TTT.AU","3DP.AU","XKO.AU","EIQ.AU","LM8.AU","BK7036","BK7117","BK7016","BK7095","XJO.AU","AEM.AU","BK7142","BK7113","BK7506","AV1.AU","BK7116","BK7508","BK7093","NWF.AU","SKS.AU","BK7017","REG.AU","BK7067","P1E.AU","SEA.AU","WZR.AU","XAO.AU","BK7023","CUV.AU"],"gpt_icon":0},{"id":"2604744915","title":"Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604744915","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604744915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:30","pubTimestamp":1768584634,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology.\nThis step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully.\nWe’ll now explore how advancing the proprietary VLRX-L...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","VLRX","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2603545606","title":"Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2603545606","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603545606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:34","pubTimestamp":1768462462,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","VLRX","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2602810564","title":"Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2602810564","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602810564?lang=en_us&edition=fundamental","pubTime":"2026-01-12 10:08","pubTimestamp":1768183730,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  started dosing in its preclinical study with its controlled-release liquid injectable platform candidate, VLRX-L, designed to control the release of peptides, according to a Monday Australian bourse filing.The study seeks to evaluate the controlled-release profile of VLRX-L candidates and determine the reproducibility of drug release using an in-vitro model, the filing said.The company seeks to complete the preclinical program in the second half of 2026.Clinuvel Pharmaceuticals' shares rose almost 2% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2601387517","title":"Clinuvel Pharmaceuticals Says Four Patients Reported Satisfaction in  Vitilgo Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387517","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601387517?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:44","pubTimestamp":1767829487,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said four patients with darker skin types enrolled in its study of drug candidate Scenesse in the treatment of vitiligo reported satisfaction with the treatment, which was also well tolerated, according to a Thursday filing with the Australian bourse.The patients had received seven implants of the drug candidate and up to 40 adjunct narrowband ultraviolet B phototherapy sessions, the filing said.Shares of the company rose 2% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2601420837","title":"Artrya And 2 Other High Growth Tech Stocks With Potential In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2601420837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601420837?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:06","pubTimestamp":1767639983,"startTime":"0","endTime":"0","summary":"As the Australian market kicks off 2026, the ASX has been relatively flat with a brief pause in the Santa Rally, while IT stocks have led declines amidst broader market uncertainties. In this environment, identifying high-growth tech stocks like Artrya and others requires careful consideration of their potential to navigate current challenges and capitalize on emerging opportunities within Australia's dynamic economic landscape.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/artrya-and-2-other-high-growth-tech-stocks-with-potential-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/artrya-and-2-other-high-growth-tech-stocks-with-potential-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","CGS.AU","AYA.AU","BK7094","XKO.AU","BK7067","XJO.AU","CUV.AU","XAO.AU"],"gpt_icon":0},{"id":"2592135240","title":"Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2592135240","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592135240?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:23","pubTimestamp":1766107403,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  filed a draft registration statement with the US Securities and Exchange Commission , seeking to uplist its American depositary receipt  program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADR.AU","BK7067","BK7508","BK4107","CUV.AU","AFG","BK4117","SEC.AU","BK7094","NQmain"],"gpt_icon":0},{"id":"2590554975","title":"Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590554975","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590554975?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:15","pubTimestamp":1765401311,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-after-vallau","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-after-vallau","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2590314785","title":"Is Clinuvel (ASX:CUV) Using Its Singapore Peptide Hub To Quietly Redefine Its Pipeline Ambitions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590314785","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590314785?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271759,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently expanded its Vallaurix research, development, and innovation hub in Singapore, backed by the Singapore Economic Development Board, to build a global center for advanced, long-acting peptide therapies and integrated formulation and analytical sciences.\nThis move strengthens Clinuvel’s push toward greater vertical integration in peptide-based medicine, aiming to speed up late-stage development programs and broaden its pipeline beyond a single flagship...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/is-clinuvel-asxcuv-using-its-singapore-peptide-hub-to-quietl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/is-clinuvel-asxcuv-using-its-singapore-peptide-hub-to-quietl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HUBG","BK7508","IE00B7SZL793.SGD","CUV.AU","IE00B66KJ199.SGD","IE0031619046.USD","BK7067","IE00B19Z4B17.USD","BK4131"],"gpt_icon":0},{"id":"2589802307","title":"BRIEF-Clinuvel Pharmaceuticals Expands Singapore Rd&I Centre To Pioneer Next-Generation Peptide Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802307","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802307?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:01","pubTimestamp":1765155670,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Expands Singapore Rd&I Centre To Pioneer Next-Generation Peptide TherapiesDec 8  - Clinuvel Pharmaceuticals Ltd CUV.AX:EXPANDS SINGAPORE RD&I CENTRE TO PIONEER NEXT-GENERATION PEPTIDE THERAPIESFurther company coverage: CUV.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XC0H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2589801107","title":"BUZZ-Australia's Clinuvel jumps on expansion of Singapore R&D hub","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801107","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801107?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:55","pubTimestamp":1765151713,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel jumps on expansion of Singapore R&D hub** Shares of Clinuvel Pharmaceuticals CUV.AX advances 2.35% to A$12.620, their highest since December 1** Biopharma co announces signif","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nL6N3XD084:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2589019568","title":"Clinuvel Expands Research, Development Center in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2589019568","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589019568?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:45","pubTimestamp":1765151147,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  expanded its Vallaurix research, development, and innovation center in Singapore with a five-year investment, supported by the Singaporean Economic Development Board, according to a Monday filing with the Australian bourse.The investment will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted, the filing said.The company's shares added 2% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2589801801","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801801","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801801?lang=en_us&edition=fundamental","pubTime":"2025-12-08 03:05","pubTimestamp":1765134332,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/exploring-3-high-growth-tech-stocks-in-australia-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/exploring-3-high-growth-tech-stocks-in-australia-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XKO.AU","BK7508","XAO.AU","CUV.AU","CGS.AU","AYA.AU","BK7094","BK7067","XJO.AU"],"gpt_icon":0},{"id":"2588880670","title":"Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880670","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588880670?lang=en_us&edition=fundamental","pubTime":"2025-12-02 10:49","pubTimestamp":1764643778,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulator","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2581046771","title":"High Growth Tech Stocks in Australia for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046771","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046771?lang=en_us&edition=fundamental","pubTime":"2025-11-07 03:06","pubTimestamp":1762455965,"startTime":"0","endTime":"0","summary":"The Australian market has been navigating a period of uncertainty, with key indices fluctuating due to geopolitical events and rising inflation, while sectors like materials have shown resilience amidst these challenges. In this environment, identifying high growth tech stocks requires focusing on companies that demonstrate robust adaptability and innovation to thrive despite broader market volatility.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-november-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-november-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7503","XKO.AU","BK7016","BK7508","XJO.AU","BK7067","BK7094","IFM.AU","CUV.AU","XAO.AU","AYA.AU"],"gpt_icon":0},{"id":"2581752570","title":"Clinuvel Pharmaceuticals (ASX:CUV): Valuation Insights After SEC Review Delay and Share Price Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2581752570","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581752570?lang=en_us&edition=fundamental","pubTime":"2025-11-04 19:35","pubTimestamp":1762256123,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) shared that the ongoing U.S. Federal government shutdown is expected to slow the review and approval of its SEC filings. The company’s share price slipped following news of the delay.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nClinuvel’s share price has steadily softened this year, with a 30-day share price return of -10.26% hinting at fading momentum. Ongoing SEC-related delays are adding to the pressure. The bigger picture shows a one-year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-insights-after-sec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-insights-after-sec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2580230202","title":"Clinuvel Pharmaceuticals Expects US Shutdown to Impact ADR Program Upgrade Deadlines","url":"https://stock-news.laohu8.com/highlight/detail?id=2580230202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580230202?lang=en_us&edition=fundamental","pubTime":"2025-11-03 08:39","pubTimestamp":1762130356,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said it expects the ongoing US Federal Government shutdown to impact the deadline for the upgrade of its American Depositary Receipt Level program from level one to level two, according to a Monday filing with the Australian bourse.The US administration expects a longer turnaround time for the review and approval of the registration statements filed with the US Securities and Exchange Commission, the filing said.The review and approval are expected to be completed only after the shutdown is resolved, the filing added.Shares of the company fell nearly 1% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2580323418","title":"Clinuvel Pharmaceuticals Ltd-Update on Adr Upgrade, Nasdaq Uplisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2580323418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580323418?lang=en_us&edition=fundamental","pubTime":"2025-11-03 06:52","pubTimestamp":1762123924,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251102:nTUE3LQXGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}